The Brinzei MDMA-PTSD Protocol

PTSD is not just a disorder of memory — it is a disorder of fear, meaning, and connection. Traditional treatments often struggle because they ask people to revisit trauma while their nervous system remains locked in threat.

The Brinzei MDMA-PTSD Protocol was developed to address this problem directly.

At its core, the protocol integrates MDMA-assisted therapy with a precise understanding of trauma neurobiology. MDMA reduces fear responses in the amygdala, increases trust and emotional safety, and enhances access to autobiographical memory. This creates a rare therapeutic window in which traumatic material can be revisited without overwhelming fear or dissociation.

The protocol is built around three principles:

1. Safety before exposure
   MDMA is used to reliably establish a state of physiological and emotional safety before any trauma processing begins.
2. Affective memory reconsolidation
   Rather than forcing narrative recall, the protocol focuses on updating trauma-encoded emotional memories — allowing new meaning, compassion, and agency to be integrated.
3. Structured integration
   Preparation and post-session integration are treated as equally critical as the dosing sessions themselves, ensuring changes are durable and embodied in daily life.

The Brinzei MDMA-PTSD Protocol is designed for clinical settings and aligns with emerging regulatory frameworks in Australia and internationally. It is not about erasing memories, but about freeing them from fear.

In doing so, the protocol offers a model of PTSD treatment that is humane, neurobiologically grounded, and deeply respectful of the patient’s lived experience.

When fear is softened, healing becomes possible.